Delving into the Latest Updates on JK1033 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

JK1033

Target-

Action-

Mechanism-

Therapeutic Areas

Respiratory DiseasesOther Diseases

Active Indication

Idiopathic Pulmonary Fibrosis

Inactive Indication-

Originator Organization

Tianjin Jikun Pharmaceutical Technology Co., Ltd.

Active Organization

Tianjin Jikun Pharmaceutical Technology Co., Ltd.

Inactive Organization-

License Organization

Baheal Pharmaceutical Group Co. Ltd.Tianjin Jikun Pharmaceutical Technology Co., Ltd.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价中国健康成年受试者单次和多次口服JK1033片后的安全性和耐受性。次要目的：评价中国健康成年受试者单次和多次口服JK1033片后的PK特征。探索性目的：初步探索JK1033片对按心率校正的QT间期（QTc）的影响；评价食物对口服JK1033片后的PK特征的影响。

[Translation]

Primary objective: To evaluate the safety and tolerability of JK1033 tablets after single and multiple oral administration in healthy Chinese adult subjects. Secondary objective: To evaluate the PK characteristics of JK1033 tablets after single and multiple oral administration in healthy Chinese adult subjects. Exploratory objective: To preliminarily explore the effect of JK1033 tablets on the QT interval corrected for heart rate (QTc); to evaluate the effect of food on the PK characteristics of JK1033 tablets after oral administration.

Start Date17 Jun 2025

Sponsor / Collaborator

Tianjin Jikun Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with JK1033

Login to view more data

100 Translational Medicine associated with JK1033

Login to view more data

100 Patents (Medical) associated with JK1033

Login to view more data

100 Deals associated with JK1033

Login to view more data